Tussin

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the facilitation of mucus clearance in patients experiencing excessive bronchial secretions. It helps to loosen phlegm and thin bronchial secretions, thereby enhancing the productivity of cough and aiding in the removal of bothersome mucus from the airways.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The recommended dosage for adults and children aged 12 years and older is 2 to 4 teaspoonfuls administered every 4 hours as needed. It is imperative that no more than 6 doses are taken within a 24-hour period to avoid potential overdose.

For children under 12 years of age, the use of this medication is not recommended. Healthcare professionals should ensure that patients adhere to the specified dosing guidelines to promote safety and efficacy.

Contraindications

There are no specified contraindications for this product. However, it is essential to adhere to the recommended dosage guidelines, as exceeding the directed use may lead to adverse effects.

Warnings and Precautions

The product must not be used if the printed seal under the cap is torn or missing, as this may indicate tampering or contamination.

Healthcare professionals should advise patients to consult a physician if they experience a cough accompanied by excessive phlegm (mucus) or if the cough is chronic, particularly in individuals with a history of smoking, asthma, chronic bronchitis, or emphysema. These conditions may require further evaluation and management.

In the event of an overdose, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay to ensure appropriate intervention.

Patients should be instructed to discontinue use and seek medical advice if their cough persists for more than 7 days, recurs, or is associated with fever, rash, or a persistent headache. These symptoms may indicate a more serious underlying condition that necessitates further investigation and treatment.

Side Effects

Patients should be aware of the following warnings and recommendations regarding the use of this product. It is imperative not to use the product if the printed seal under the cap is torn or missing. Additionally, patients are advised to consult a doctor if they experience a cough accompanied by excessive phlegm (mucus) or if the cough is chronic, such as that associated with smoking, asthma, chronic bronchitis, or emphysema.

Patients should discontinue use and seek medical advice if their cough persists for more than 7 days, recurs, or is accompanied by fever, rash, or a persistent headache. These symptoms may indicate a serious underlying condition that requires further evaluation.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Tussin (guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should not use this medication. For adolescents aged 12 years and older, the recommended dosage is 2 to 4 teaspoonfuls every 4 hours, with a maximum of 6 doses in any 24-hour period.

It is essential to keep this medication out of reach of children. In the event of an overdose, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

Geriatric Use

There is no specific information regarding the use of TUSSIN (guaifenesin liquid) in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as they may have altered pharmacokinetics and increased sensitivity to medications. Monitoring for efficacy and adverse effects is recommended in this population, given the lack of targeted data.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is important to assess the potential risks and benefits associated with its use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is no specific data available regarding the excretion of this medication in breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment may require dosage adjustments due to reduced renal function. It is essential to monitor renal function tests regularly in patients with known kidney problems to ensure appropriate dosing. A reduced dose should be considered for patients with a creatinine clearance below a specified threshold. Additionally, special monitoring is necessary for patients with severe renal impairment to mitigate potential risks associated with their condition.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary significantly depending on the substance involved and the individual patient’s characteristics. Symptoms may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate assessment of the patient's condition is critical. Recommended actions include:

1. Assessment: Conduct a thorough evaluation of the patient's vital signs and clinical status.

2. Supportive Care: Initiate supportive measures as necessary, including airway management, oxygen supplementation, and intravenous fluids.

3. Decontamination: If appropriate and within a reasonable time frame, consider gastrointestinal decontamination methods such as activated charcoal, provided the patient is alert and able to protect their airway.

4. Specific Antidotes: If a specific antidote is available for the substance involved, it should be administered according to established protocols.

Healthcare professionals are encouraged to consult local poison control centers or toxicology experts for guidance on management strategies tailored to the specific circumstances of the overdose. Continuous monitoring and supportive care are paramount until the patient stabilizes or further interventions are deemed necessary.

Documentation of the incident, including the substance involved, estimated dose, time of exposure, and clinical findings, is crucial for ongoing management and future reference.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to keep this product out of reach of children. In the event of an overdose, patients should seek medical assistance or contact a Poison Control Center immediately.

Patients should be informed to discontinue use and consult a doctor if their cough persists for more than 7 days, returns, or is accompanied by fever, rash, or a persistent headache, as these symptoms may indicate a serious condition.

Additionally, healthcare providers should emphasize the importance of adhering to the recommended dosage and instruct patients not to exceed the directed amount while using this product.

Storage and Handling

The product is supplied in a carton that contains a dosing cup for accurate measurement. It is essential to store the product at a temperature range of 20°-25°C (68°-77°F). Refrigeration is not recommended, as it may affect the product's integrity. Users should retain the carton to access the full Directions for use, ensuring proper handling and administration.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Tussin, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)